Latest 10-K annual reports

Dakota Gold Corp.'s 2025 annual report details significant progress at its Richmond Hill Gold Project, ongoing exploration, and financial results, including a net loss of $29.5 million.

Exicure, Inc. reports a net loss of $4.9 million for 2025, continues to explore strategic alternatives, and faces substantial doubt about its ability to continue as a going concern.

The Cato Corporation reported a significant reduction in net loss and a modest increase in retail sales for fiscal 2025, despite ongoing challenges from tariffs and store closures.

Texas Community Bancshares, Inc. reported a significant turnaround in 2025, achieving a net income of $2.8 million compared to a net loss in the prior year, driven by strategic balance sheet repositioning and increased net interest income.

MaxCyte reported a wider net loss of $44.6 million in 2025, driven by decreased core revenue and a workforce reduction, despite strategic acquisition and platform expansion.

BeyondSpring Inc. reported a net loss of $14.2 million for 2025, while advancing its lead asset Plinabulin in NSCLC and its SEED Therapeutics' TPD platform into clinical studies.

KalVista Pharmaceuticals reports its first product revenue following FDA approval and global authorizations for EKTERLY, an oral on-demand therapy for HAE, while securing significant financing.

ProMIS Neurosciences reports significant progress in its lead Alzheimer's disease clinical trial, PMN310, and strengthens its financial position with recent capital raises.

MineralRite Corporation, a development-stage mineral and mine management company, reported a net loss of $291,519 for 2025 as it continues to focus on strategic asset acquisition and regulatory compliance.

Stran & Company, Inc. reported a 40.6% increase in total sales to $116.2 million for 2025, narrowing its net loss to $0.7 million from $4.1 million in 2024, driven by client spending and strategic acquisitions.

Calisa Acquisition Corp, a SPAC, has entered into a definitive merger agreement with Goodvision AI Inc. but faces substantial doubt about its ability to continue as a going concern.

X3 Acquisition Corp. filed its annual report, outlining its blank check company structure, successful IPO, and strategy to target financial services businesses.

Cohen Circle Acquisition Corp. II, a SPAC focused on fintech, reported a net income of $4.36 million for 2025, primarily from trust account interest, as it continues its search for an initial business combination.

Lafayette Digital Acquisition Corp. I, a SPAC, outlines its corporate structure, recent IPO, and strategic focus on digital assets and financial technology in its latest 10-K filing.

TPI Composites, an independent wind blade manufacturer, filed for Chapter 11 bankruptcy, was delisted from Nasdaq, and is selling substantially all its assets amid significant financial and operational challenges.

GCT Semiconductor reported a significant increase in net loss for 2025, driven by reduced 4G sales and ongoing 5G development costs, despite initial 5G product shipments and new capital raise efforts.

Reeds Inc. reported a significant increase in net loss for fiscal year 2025, driven by declining sales and higher operating expenses, despite strategic investments in Asia-Pacific expansion and recent capital raises.

Armata Pharmaceuticals reports positive Phase 2a data for AP-SA02 in complicated S. aureus bacteremia, receives QIDP designation, and plans for Phase 3, but faces substantial doubt about its ability to continue as a going concern.

Planet 13 Holdings Inc. reported a significant revenue decline and net loss in 2025, driven by market price compression and strategic exits, while expanding its Florida dispensary network.

EDAP TMS S.A. reported a 1.6% increase in total revenues to $70.5 million in 2025, driven by strong HIFU growth, while facing a net loss of $29.2 million and strategic shifts away from legacy businesses.

Equillium, a biotechnology company, reported significant losses for 2025 but secured $35 million in March 2026 to fund the advancement of its lead candidate, EQ504, into Phase 1 clinical trials by mid-2026.

Dyadic International, Inc. rebranded as Dyadic Applied BioSolutions, shifting its strategy to commercialize non-pharmaceutical proteins while reporting a wider net loss in 2025 despite new grant funding.

Gulf Coast Ultra Deep Royalty Trust reports no distributable income for 2025 and 2024, with future distributions dependent on a newly drilled well whose production status remains unknown.

Toppoint Holdings Inc. reported a net loss of $7.34 million for the fiscal year ended December 31, 2025, despite a 3% increase in total revenue to $16.55 million, driven by growth in scrap metal and import freight.

SOLV Energy, a leading power infrastructure services provider, announced significant revenue and profit growth in its 2025 annual report, driven by new construction and strategic acquisitions, while completing its initial public offering.

Modiv Industrial, Inc. reports a strategic shift to industrial properties, increased distributions, and a net loss for fiscal year 2025 amidst market uncertainties.

Medicus Pharma Ltd. announced positive Phase 2 clinical trial results for its D-MNA skin cancer treatment and provided updates on its Teverelix program and financing activities, despite ongoing operating losses and a going concern warning.

Nkarta, Inc. reports a strategic pivot to autoimmune disease therapies with its lead candidate NKX019, alongside reduced net losses and a strong cash position for the next 12 months.

WidePoint Corporation reported a 6% increase in annual revenue to $150.5 million for 2025, alongside an 11% rise in gross profit, but saw its net loss widen to $2.75 million.

TELA Bio, a medical technology company, reported a 16% increase in revenue to $80.3 million for 2025, alongside a net loss of $38.8 million, as it expands its soft-tissue reconstruction product portfolio.